Kirkland & Ellis LLP advised Bristol Myers Squibb, while Skadden, Arps, Slate, Meagher & Flom LLP advised Mirat on the deal. Bristol Myers Squibb (NYSE: BMY)...
Mirati Therapeutics’ Merger With Bristol Myers Squibb
Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...